We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with dermatomyositis or ...
PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
A 37-year-old female who had undergone a matched unrelated allogeneic BMT 2 years prior to admission presented with a several month history of progressive weakness of the muscles of both shoulders, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback